Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Pancreatic Neoplasms 11 Breast Neoplasms 8 Prostatic Neoplasms 7 Colorectal Neoplasms 7 Carcinoma, Non-Small-Cell Lung 6 Neoplasms 5 Melanoma 5 COVID-19 4 Multiple Myeloma 3 Lung Neoplasms 3 Gastrointestinal Neoplasms 3 Colonic Neoplasms 3 Carcinoma, Renal Cell 3 Unspecified Adult Solid Tumor, Protocol Specific 2 Solid Tumor 2 Recurrence 2 Rectal Neoplasms 2 Ovarian Neoplasms 2 Neoplasms, Plasma Cell 2 Neoplasm Metastasis 2 Leukemia 2 Glioblastoma 2 Cholangiocarcinoma 2 Adenocarcinoma of Lung 2 Adenocarcinoma 2 Urologic Diseases 1 Untreated Resectable Pancreatic Adenocarcinoma 1 Small Cell Lung Carcinoma 1 Sarcoma, Clear Cell 1 Sarcoma 1

Interventions

Cyclophosphamide 87 fludarabine 77 fludarabine phosphate 45 Tacrolimus 45 Whole-Body Irradiation 42 Mycophenolic Acid 42 Busulfan 35 Melphalan 32 Antilymphocyte Serum 24 Methotrexate 23 thymoglobulin 22 Standard of Care 22 Rituximab 22 venetoclax 20 Thiotepa 20 Sirolimus 20 Azacitidine 20 Stem Cell Transplantation 18 Granulocyte Colony-Stimulating Factor 18 Practice Guidelines as Topic 17 Cytarabine 16 Bortezomib 16 Nivolumab 15 Filgrastim 15 Specimen Handling 14 Dexamethasone 14 Blood Specimen Collection 14 Cyclosporine 13 Surveys and Questionnaires 12 Mesna 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Hematologic Neoplasms × Hydroxychloroquine × Clear all

NCT04392128 2020-09-04

HYACINTHE

Institut de cancérologie Strasbourg Europe

Phase 2 Withdrawn

Other hematologic neoplasm

COVID-19, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡